Progress in the study of interleukin-17A-mediated signaling network regulating airway remodeling in asthma

doi:10.12092/j.issn.1009-2501.2026.01.010

Abstract

Abstract:

Asthma is an immune inflammatory disease. Repeated inflammatory responses cause "damage-repair" to reshape the airway structure (known as "airway remodeling"), and airway remodeling is the main cause of irreversible reduction in lung function in asthma patients. Interleukin-17A (IL-17A), as a special subtype of IL-17, plays a key regulatory role in the pathological changes of airway remodeling, such as airway inflammation, goblet cell (GC) metaplasia, high expression of mucin (Muc), and smooth muscle (ASM) thickening in asthma. Therefore, IL-17A regulation of the signal network related to airway remodeling in asthma has become a new research hotspot in recent years. This article reviews the mechanism of IL-17A regulating airway remodeling in asthma from the perspective of signal networks such as retinoic acid-related orphan receptor γt (RORγt), signal transducer and activator of transcription 3 (STAT3), transforming growth factor-β1 (TGF-β1), nuclear factor-κB (NF-κB), and p38 mitogen-activated protein kinase (p38 MAPK), providing a theoretical basis for the study of the mechanism of airway remodeling in asthma and the development of new drugs.

Key words: bronchial asthma (asthma), airway remodeling, interleukin-17A, signaling network

CLC Number:

R562.25
R966

Zhiwang WANG, Yue ZHANG, Ping QUAN, Yue ZHAO, Bei TIAN, Haijing DUAN, Ruiqiong WANG. Progress in the study of interleukin-17A-mediated signaling network regulating airway remodeling in asthma[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(1): 88-95.

Figures/Tables 2

References 51

1	黄柯婷, 王志旺, 梁可克, 等. IL-13 激活杯状细胞参与哮喘气道黏液高分泌的研究新进展[J]. 中国现代应用药学, 2023, 40 (10): 1416- 1421. doi: 10.13748/j.cnki.issn1007-7693.20221880
2	Wang X, Gao Y, Yang Q, et al. Pingchuanning decoction attenuates airway inflammation by suppressing autophagy via phosphatidylinositol 3‐kinase/protein kinase B/mammalian target of rapamycin signaling pathway in rat models of asthma[J]. J Cell Biochem, 2019, 120 (3): 3833- 3844. doi: 10.1002/jcb.27665
3	中国医药教育协会慢性气道疾病专业委员会, 中国哮喘联盟. 重度哮喘诊断与处理中国专家共识(2024)[J]. 中华医学杂志, 2024, 104 (20): 1759- 1789. doi: 10.3760/cma.j.cn112137-20231117-01120
4	Varricchi G, Brightling CE, Grainge C, et al. Airway remodelling in asthma and the epithelium: On the edge of a new era[J]. Eur Respir J, 2024, 63 (4): 2301619. doi: 10.1183/13993003.01619-2023
5	席建宏, 黄柯婷, 王志旺, 等. PI3K/Akt信号通路调控哮喘气道黏液高分泌的研究现状[J]. 中国临床药理学杂志, 2022, 38 (22): 2779- 2782.
6	Hynes GM, Hinks TSC. The role of interleukin-17 in asthma: a protective response?[J]. ERJ Open Res, 2020, 6 (2): 00364- 2019. doi: 10.1183/23120541.00364-2019
7	Ritzmann F, Lunding LP, Bals R, et al. IL-17 cytokines and chronic lung diseases[J]. Cells, 2022, 11 (14): 2132. doi: 10.3390/cells11142132
8	徐蕾, 贺新华, 陈昂, 等. 支气管哮喘患者外周血蛋白磷酸酶1A水平与气道重塑的关系[J]. 中国医药导报, 2021, 18 (25): 98- 102. doi: 10.20047/j.issn1673-7210.2021.25.023
9	Yu Q, Shi YJ, Shu C, et al. Andrographolide inhibition of Th17‐regulated cytokines and JAK1/STAT3 signaling in OVA‐stimulated asthma in mice[J]. Evid Based Complement Alternat Med, 2021, 2021 (1): 6862073.
10	Rex DAB, Dagamajalu S, Gouda MM, et al. A comprehensive network map of IL-17A signaling pathway[J]. J Cell Commun Signal, 2023, 17 (1): 209- 215. doi: 10.1007/s12079-022-00686-y
11	Jetten AM, Cook DN. (Inverse) agonists of retinoic acid–related orphan receptor γ: regulation of immune responses, inflammation, and autoimmune disease[J]. Annu Rev Pharmacol Toxicol, 2020, 60 (1): 371- 390. doi: 10.1146/annurev-pharmtox-010919-023711
12	Kumar R, Theiss AL, Venuprasad K. RORγt protein modifications and IL-17-mediated inflammation[J]. Trends Immunol, 2021, 42 (11): 1037- 1050. doi: 10.1016/j.it.2021.09.005
13	Xie Y, Abel PW, Casale TB, et al. TH17 cells and corticosteroid insensitivity in severe asthma[J]. J Allergy Clin Immunol, 2022, 149 (2): 467- 479. doi: 10.1016/j.jaci.2021.12.769
14	Li H, Ye Q, Lin Y, et al. CpG oligodeoxynucleotides attenuate RORγt-mediated Th17 response by restoring histone deacetylase-2 in cigarette smoke-exposure asthma[J]. Cell Biosci, 2021, 11 (1): 92. doi: 10.1186/s13578-021-00607-3
15	周亚兵, 蒋思韵, 王利维, 等. PM2.5对哮喘大鼠IL-17/IL-23炎症介质的影响及人参皂苷Rg1干预研究[J]. 世界中医药, 2021, 16 (10): 1520- 1525.
16	Lamb D, De Sousa D, Quast K, et al. RORγt inhibitors block both IL-17 and IL-22 conferring a potential advantage over anti-IL-17 alone to treat severe asthma[J]. Respir Res, 2021, 22 (1): 158. doi: 10.1186/s12931-021-01743-7
17	Nikolskii AA, Shilovskiy IP, Barvinskaia ED, et al. Role of STAT3 transcription factor in pathogenesis of bronchial asthma[J]. Biochemistry (Mosc), 2021, 86 (11): 1489- 1501. doi: 10.1134/s0006297921110122
18	Gavino AC, Nahmod K, Bharadwaj U, et al. STAT3 inhibition prevents lung inflammation, remodeling, and accumulation of Th2 and Th17 cells in a murine asthma model[J]. Allergy, 2016, 71 (12): 1684- 1692. doi: 10.1111/all.12937
19	Camargo LN, Santos TM, Andrade FCP, et al. Bronchial vascular remodeling is attenuated by anti-IL-17 in asthmatic responses exacerbated by LPS[J]. Front Pharmacol, 2020, 11, 1269. doi: 10.3389/fphar.2020.01269
20	吕川, 朱慧志, 刘向国, 等. 基于IL-6/JAK2/STAT3信号轴研究阳和平喘颗粒调控哮喘大鼠气道重塑作用机制[J]. 海南医学院学报, 2024, 30 (1): 15- 20+28. doi: 10.13210/j.cnki.jhmu.20231030.001
21	Zhang Y, Chen L, Ouyang H. Shikonin alleviates asthma phenotypes in mice via an airway epithelial STAT3-dependent mechanism[J]. Open Med (Wars), 2024, 19 (1): 20241016. doi: 10.1515/med-2024-1016
22	Chen H, Guo SX, Zhang S, et al. MiRNA‐620 promotes TGF‐β1‐induced proliferation of airway smooth muscle cell through controlling PTEN/AKT signaling pathway[J]. Kaohsiung J Med Sci, 2020, 36 (11): 869- 877.
23	Park YH, Oh EY, Han H, et al. Insulin resistance mediates high-fat diet-induced pulmonary fibrosis and airway hyperresponsiveness through the TGF-β1 pathway[J]. Exp Mol Med, 2019, 51 (5): 1- 12. doi: 10.1038/s12276-019-0258-7
24	Zheng Y, Li L, Cai T. Cordyceps polysaccharide ameliorates airway inflammation in an ovalbumin-induced mouse model of asthma via TGF-β1/Smad signaling pathway[J]. Respir Physiol Neurobiol, 2020, 276, 103412. doi: 10.1016/j.resp.2020.103412
25	Huang S, Zhou R, Yuan Y, et al. Stigmasterol alleviates airway inflammation in OVA-induced asthmatic mice via inhibiting the TGF-β1/Smad2 and IL-17A signaling pathways[J]. Aging (Albany NY), 2024, 16 (7): 6478. doi: 10.18632/aging.205716
26	Kim DI, Song MK, Lee K. Diesel exhaust particulates enhances susceptibility of LPS-induced acute lung injury through upregulation of the IL-17 cytokine-derived TGF-β1/collagen I expression and activation of NLRP3 inflammasome signaling in mice[J]. Biomolecules, 2021, 11 (1): 67. doi: 10.3390/biom11010067
27	Li H, Lin Y, Ye Q, et al. Airway inflammation and remodeling of cigarette smoking exposure ovalbumin-induced asthma is alleviated by CpG oligodeoxynucleotides via affecting dendritic cell-mediated Th17 polarization[J]. Int Immunopharmacol, 2020, 82, 106361. doi: 10.1016/j.intimp.2020.106361
28	Liu D, Zhong Z, Karin M. NF-κB: a double-edged sword controlling inflammation[J]. Biomedicines, 2022, 10 (6): 1250. doi: 10.3390/biomedicines10061250
29	Liao H, Chang X, Gao L, et al. IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer[J]. J Transl Med, 2023, 21 (1): 828. doi: 10.1186/s12967-023-04365-3
30	Mohammadi B, Saghafi M, Khorasani AM, et al. Different levels of MUC5AC and MUC5B genes expression in severe allergic versus non-allergic asthma[J]. Life Res, 2022, 5 (4): 26. doi: 10.53388/2022-0515-501
31	程慧雯, 袁文清, 魏水清, 等. miRNA-133b激活剂对过敏性鼻炎-哮喘综合征小鼠气道炎症的影响[J]. 青岛大学学报(医学版), 2022, 58 (5): 733- 738. doi: 10.11712/jms.2096-5532.2022.58.123
32	Kudo M, Melton AC, Chen C, et al. IL-17A produced by αβ T cells drives airway hyper-responsiveness in mice and enhances mouse and human airway smooth muscle contraction[J]. Nat Med, 2012, 18 (4): 547- 554. doi: 10.1038/nm.2684
33	Song JL, Qian B, Pan C, et al. Protective activity of mogroside V against ovalbumin‐induced experimental allergic asthma in Kunming mice[J]. J Food Biochem, 2019, 43 (9): e12973. doi: 10.1111/jfbc.12973
34	Machado TR, Machado TR, Pascutti PG. The p38 MAPK inhibitors and their role in inflammatory diseases[J]. ChemistrySelect, 2021, 6 (23): 5729- 5742. doi: 10.1002/slct.202100406
35	Saleem S. Targeting MAPK signaling: a promising approach for treating inflammatory lung disease[J]. Pathol Res Pract, 2024, 254, 155122. doi: 10.1016/j.prp.2024.155122
36	Wang G, Pang Z, Hsu ACY, et al. Combined treatment with SB203580 and dexamethasone suppresses non-typeable Haemophilus influenzae-induced Th17 inflammation response in murine allergic asthma[J]. Eur J Pharmacol, 2019, 862, 172623. doi: 10.1016/j.ejphar.2019.172623
37	彭小芝, 马朝芝, 夏雨, 等. 毛喉鞘蕊花提取物对大鼠哮喘模型炎症介质的影响及机制研究[J]. 天然产物研究与开发, 2019, 31 (9): 1515- 1519. doi: 10.16333/j.1001-6880.2019.9.005
38	Ferreira LKDP, Ferreira LAMP, Barros GCB, et al. MHTP, a synthetic alkaloid, attenuates combined allergic rhinitis and asthma syndrome through downregulation of the p38/ERK1/2 MAPK signaling pathway in mice[J]. Int Immunopharmacol, 2021, 96, 107590. doi: 10.1016/j.intimp.2021.107590
39	Tota M, Łacwik J, Laska J, et al. The role of eosinophil-derived neurotoxin and vascular endothelial growth factor in the pathogenesis of eosinophilic asthma[J]. Cells, 2023, 12 (9): 1326. doi: 10.3390/cells12091326
40	阿依妮葛尔·麦麦提艾力, 阿布里米提·阿不列里木, 窦勤, 等. 基于TGF-β1/Smad2/3信号通路探讨茴香胶囊抗支气管哮喘作用及机制[J]. 中南药学, 2024, 22 (8): 2025- 2032. doi: 10.7539/j.issn.1672-2981.2024.08.010
41	Razaghian A, Parvaneh N, Amirzargar AA, et al. Tumor necrosis factor-α (-308G> A) gene polymorphism and its association with asthma and atopy status[J]. Iran J Allergy Asthma Immunol, 2023, 22 (4): 337- 344. doi: 10.18502/ijaai.v22i4.13606
42	Sgambellone S, Marri S, Catarinicchia S, et al. Adenosine A3 receptor (A3AR) agonist for the treatment of bleomycin-induced lung fibrosis in mice[J]. Int J Mol Sci, 2022, 23 (21): 13300. doi: 10.3390/ijms232113300
43	Chen L, Hou W, Liu F, et al. Blockade of NLRP3/Caspase-1/IL-1β regulated Th17/Treg immune imbalance and attenuated the neutrophilic airway inflammation in an ovalbumin-induced murine model of asthma[J]. J Immunol Res, 2022, 2022 (1): 9444227. doi: 10.1155/2022/9444227
44	陈凌, 茅松, 朱若尘, 等. NLRP3抑制剂MCC950对中性粒细胞性哮喘气道炎症的影响及其作用机制[J]. 中国生物制品学杂志, 2022, 35 (7): 829- 835. doi: 10.13200/j.cnki.cjb.003652
45	Song M, Liang J, Wang L, et al. IL-17A functions and the therapeutic use of IL-17A and IL-17RA targeted antibodies for cancer treatment[J]. Int Immunopharmacol, 2023, 123, 110757. doi: 10.1016/j.intimp.2023.110757
46	Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti–IL-17 receptor monoclonal antibody, in moderate to severe asthma[J]. Am J Respir Crit Care Med, 2013, 188 (11): 1294- 1302. doi: 10.1164/rccm.201212-2318OC
47	Vicovan AG, Petrescu DC, Constantinescu D, et al. Experimental insights on the use of Secukinumab and Magnolol in acute respiratory diseases in mice[J]. Biomedicines, 2024, 12 (7): 1538. doi: 10.3390/biomedicines12071538
48	Berry SPDG, Dossou C, Kashif A, et al. The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases[J]. Int Immunopharmacol, 2022, 102, 108402. doi: 10.1016/j.intimp.2021.108402
49	Plichta J, Kuna P, Panek M. Biologic drugs in the treatment of chronic inflammatory pulmonary diseases: recent developments and future perspectives[J]. Front Immunol, 2023, 14, 1207641. doi: 10.3389/fimmu.2023.1207641
50	Duchesne M, Okoye I, Lacy P. Epithelial cell alarmin cytokines: Frontline mediators of the asthma inflammatory response[J]. Front Immunol, 2022, 13, 975914. doi: 10.3389/fimmu.2022.975914
51	Evasovic JM, Singer CA. Regulation of IL-17A and implications for TGF-β1 comodulation of airway smooth muscle remodeling in severe asthma[J]. Am J Physiol Lung Cell Mol Physiol, 2019, 316 (5): L843- L868. doi: 10.1152/ajplung.00416.2018

信号网络	有效组分/ 小分子抑制剂	不同效应及组织病理变化	作用机制	参考文献
RORγt	CpG寡脱氧核苷酸	恢复Th17细胞免疫平衡；抑制气道上皮GC增生、Muc5ac高表达；减少沉积；气道壁变薄	下调RORγt、IL-17A表达	[14]
	人参皂苷Rg1	减轻炎症反应	IL-17A与RORγt表达下调	[15]
	BIX119（RORγt抑制剂）	缓解气道炎症反应；降低气道高反应性	抑制IL-17A/RORγt信号通路	[16]
STAT3	阳和平喘颗粒	减轻炎症细胞浸润；抑制上皮下胶原纤维沉积	IL-17A、 STAT3表达下调	[20]
STAT3	紫草素	抑制GC增生、Muc5ac高表达	下调IL-17A、p-STAT3的表达	[21]
TGF-β1	豆甾醇	减少炎症细胞数量；抑制ASMCs增殖	IL-17A、TGF-β1蛋白表达下调	[25]
TGF-β1	CpG寡脱氧核苷酸	气道壁变薄；减少胶原沉积	下调 IL-17A、TGF-β1表达	[27]
NF-κB	microRNA-133b	缓解气道黏液高分泌；ASM变薄	下调IL-17A、NF-κB表达	[31]
	BAY11-7082 （NF-κB小分子抑制剂）	减缓ASM紧张度；降低气道高反应性	抑制NF-κB核转位	[32]
	罗汉果苷V	减少炎症细胞浸润；抑制GC增生、ASMCs增殖；降低气道高反应性	阻断IL-17A/NF-κB信号通路	[33]
p38 MAPK	SB203580 （p38 MAPK抑制剂）	减轻气道炎症；抑制GC分化；Muc5ac高表达；提高气道顺应性	下调IL-17A、p38 MAPK 表达	[36]
	毛喉鞘蕊花提取物	抑制GC增生；减缓ASM紧张度	IL-17A、p38 MAPK表达下降	[37]
	合成生物碱	抑制ECM沉积	下调IL-17A/p38 MAPK信号通路	[38]
VEGF	茴香胶囊	降低气道胶原沉积占比；减缓支气管管壁紧张度；改善肺组织纤维化	IL-17A、VEGF mRNA表达下调	[40]
TNF-α	MRS5980 （腺苷受体激动剂）	抑制GC化生与胶原沉积；ASM变薄	IL-17A、TNF-α表达下调	[42]
NLRP3	MCC950 （NLRP3抑制剂）	减轻炎症反应	下调NLRP3炎症小体活性	[44]

信号网络	有效组分/ 小分子抑制剂	不同效应及组织病理变化	作用机制	参考文献
RORγt	CpG寡脱氧核苷酸	恢复Th17细胞免疫平衡；抑制气道上皮GC增生、Muc5ac高表达；减少沉积；气道壁变薄	下调RORγt、IL-17A表达	[14]
	人参皂苷Rg1	减轻炎症反应	IL-17A与RORγt表达下调	[15]
	BIX119（RORγt抑制剂）	缓解气道炎症反应；降低气道高反应性	抑制IL-17A/RORγt信号通路	[16]
STAT3	阳和平喘颗粒	减轻炎症细胞浸润；抑制上皮下胶原纤维沉积	IL-17A、 STAT3表达下调	[20]
STAT3	紫草素	抑制GC增生、Muc5ac高表达	下调IL-17A、p-STAT3的表达	[21]
TGF-β1	豆甾醇	减少炎症细胞数量；抑制ASMCs增殖	IL-17A、TGF-β1蛋白表达下调	[25]
TGF-β1	CpG寡脱氧核苷酸	气道壁变薄；减少胶原沉积	下调 IL-17A、TGF-β1表达	[27]
NF-κB	microRNA-133b	缓解气道黏液高分泌；ASM变薄	下调IL-17A、NF-κB表达	[31]
	BAY11-7082 （NF-κB小分子抑制剂）	减缓ASM紧张度；降低气道高反应性	抑制NF-κB核转位	[32]
	罗汉果苷V	减少炎症细胞浸润；抑制GC增生、ASMCs增殖；降低气道高反应性	阻断IL-17A/NF-κB信号通路	[33]
p38 MAPK	SB203580 （p38 MAPK抑制剂）	减轻气道炎症；抑制GC分化；Muc5ac高表达；提高气道顺应性	下调IL-17A、p38 MAPK 表达	[36]
	毛喉鞘蕊花提取物	抑制GC增生；减缓ASM紧张度	IL-17A、p38 MAPK表达下降	[37]
	合成生物碱	抑制ECM沉积	下调IL-17A/p38 MAPK信号通路	[38]
VEGF	茴香胶囊	降低气道胶原沉积占比；减缓支气管管壁紧张度；改善肺组织纤维化	IL-17A、VEGF mRNA表达下调	[40]
TNF-α	MRS5980 （腺苷受体激动剂）	抑制GC化生与胶原沉积；ASM变薄	IL-17A、TNF-α表达下调	[42]
NLRP3	MCC950 （NLRP3抑制剂）	减轻炎症反应	下调NLRP3炎症小体活性	[44]

[1]	HAN Chao, YANG Liu, ZHANG Qiuling, PAN Jinqiang, XU Jun. Effect of baicalin on airway remodeling of bronchial asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 749-754.
[2]	YAN Gui-ming, WANG Chang-zhong, ZHANG Chuan-ying, LI Yue-yue, ZHOU Xue-chun. Experimental study on interventional effect of paeonol on airway remodeling in COPD rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 499-504.
[3]	ZHENG Mei-mei, WANG Fang-jian, YUE Tie-gang, DONG Li-yan, DUAN Cheng-cheng. Effects of azithromycin on lung function and serum CTGF of asthma patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(2): 194-197.
[4]	SONG Ze-qing, ZHU Yan-fen, YAO Wei-min, WANG Hui. Effects of astragalus polysaccharide on airway remodelling in the asthma modle of mouse [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(4): 385-390.
[5]	ZHENG Yang-ming, LI Chang-chong, Zhang Wei-xi, GUAN Xiao-jun. Expression of phospho-p38MAPK in asthmatic rats with airway remodeling the effect on proliferation of mucous cells and the regulation of budesonide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(8): 866-871.
[6]	LIN Jie, DAI Yuan-rong, ZHAO Chu-huan, WENG Hai-xia, XIA Xiao-dong, HE Jian-bo. Effects of roxithromycin on myofibroblast, TGF-β₁ and IFN-γin rats asthma airway remodeling [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(10): 1116-1121.
[7]	ZHANG Wei, LIN Yong. Effect of tranilast on airway remodeling of experimental COPD rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(11): 1239-1242.
[8]	XIE Wei-ping, DING Jian-hua, WANG Hong, Xu Qi, WANG Hai, HU Gang. Effects of novel K_ATPCO iptakalim on airway hyperresponsiveness and remodeling in guinea-pigs with asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(2): 128-132.